动物实验已表明,流感病毒神经氨酸酶（NA）能诱导保护性但保留一定感染性的免疫力。免疫后用病毒进行攻击感染,虽有少量病毒复制及轻微的临床症状,但足以提供抗原刺激和肯定的免疫力。由于常规灭活疫苗无法满足大规模接种的需要,作者制备了一种适用于Ⅰ期（免疫原性和毒性）人体试验的纯化NA疫苗,并对其进行了鉴定。 Animal experiments have shown that the influenza virus neuraminidase (NA) can induce a protective but retain a certain infectivity of the immune system. Vaccination with viruses after immunization, although a small amount of viral replication and mild clinical symptoms, but sufficient to provide antigen stimulation and positive immunity. Since conventional inactivated vaccines can not meet the needs of large-scale inoculation, the authors prepared and identified a purified NA vaccine suitable for stage I (immunogenicity and toxicity) human trials.